CHO Pharma (TPEX:6586) - Share price, News & Analysis

6586 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

6586 Stock Overview

CHO Pharma, Inc., a biopharmaceutical company, develops and commercializes therapeutic and diagnostic products for the unmet clinical needs.

Rewards

Earnings have grown 1.3% per year over the past 5 years

Risk Analysis

Highly volatile share price over the past 3 months

Makes less than USD$1m in revenue (NT$4M)

CHO Pharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CHO Pharma
Historical stock prices
Current Share Price	NT$149.00
52 Week High	NT$251.50
52 Week Low	NT$25.95
Beta	0.051
1 Month Change	-39.18%
3 Month Change	-9.70%
1 Year Change	426.50%
3 Year Change	386.93%
5 Year Change	n/a
Change since IPO	79.52%

Recent News & Updates

Mar 24

Here's Why We're Not Too Worried About CHO Pharma's (GTSM:6586) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Dec 09

We're Not Very Worried About CHO Pharma's (GTSM:6586) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Shareholder Returns

	6586	TW Pharmaceuticals	TW Market
7D	-6.3%	-4.6%	-3.4%
1Y	426.5%	3.0%	0.7%

Return vs Industry: 6586 exceeded the TW Pharmaceuticals industry which returned 3% over the past year.

Return vs Market: 6586 exceeded the TW Market which returned 0.7% over the past year.

Price Volatility

Is 6586's price volatile compared to industry and market?
6586 volatility
6586 Average Weekly Movement	16.2%
Pharmaceuticals Industry Average Movement	5.4%
Market Average Movement	4.6%
10% most volatile stocks in TW Market	8.3%
10% least volatile stocks in TW Market	2.1%

Stable Share Price: 6586 is more volatile than 90% of TW stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: 6586's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of TW stocks.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	n/a	https://www.chopharma.com

CHO Pharma, Inc., a biopharmaceutical company, develops and commercializes therapeutic and diagnostic products for the unmet clinical needs. It is developing homogeneous antibody drugs, such as CHO-H01, CHO-H02, and CHO-A04 for cancer; CHO-H03, a homogeneous antibody drug for autoimmune diseases; CHO-S05 dual-effect anti-flu drugs; and CHO-V07 glycan-based vaccines and drugs. The company was founded in 2013 and is based in Taipei City, Taiwan.

CHO Pharma Fundamentals Summary

How do CHO Pharma's earnings and revenue compare to its market cap?
6586 fundamental statistics
Market Cap	NT$27.41b
Earnings (TTM)	-NT$205.92m
Revenue (TTM)	NT$3.57m

7,680x

P/S Ratio

-133.1x

P/E Ratio

Is 6586 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
6586 income statement (TTM)
Revenue	NT$3.57m
Cost of Revenue	NT$211.00k
Gross Profit	NT$3.36m
Other Expenses	NT$209.28m
Earnings	-NT$205.92m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-1.12
Gross Margin	94.09%
Net Profit Margin	-5,768.21%
Debt/Equity Ratio	0%

How did 6586 perform over the long term?

See historical performance and comparison

Valuation

Is CHO Pharma undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

15.72x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6586's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 6586's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: 6586 is unprofitable, so we can't compare its PE Ratio to the TW Pharmaceuticals industry average.

PE vs Market: 6586 is unprofitable, so we can't compare its PE Ratio to the TW market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6586's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 6586 is overvalued based on its PB Ratio (15.7x) compared to the TW Pharmaceuticals industry average (2x).

Future Growth

How is CHO Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

50.2%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CHO Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has CHO Pharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

1.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 6586 is currently unprofitable.

Growing Profit Margin: 6586 is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: 6586 is unprofitable, but has reduced losses over the past 5 years at a rate of 1.3% per year.

Accelerating Growth: Unable to compare 6586's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6586 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-7.6%).

Return on Equity

High ROE: 6586 has a negative Return on Equity (-11.81%), as it is currently unprofitable.

Financial Health

How is CHO Pharma's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: 6586's short term assets (NT$1.3B) exceed its short term liabilities (NT$133.2M).

Long Term Liabilities: 6586's short term assets (NT$1.3B) exceed its long term liabilities (NT$16.5M).

Debt to Equity History and Analysis

Debt Level: 6586 is debt free.

Reducing Debt: 6586 has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6586 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 6586 has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 7.7% each year

Dividend

What is CHO Pharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6586's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6586's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6586's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6586's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 6586 has not reported any payouts.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average board tenure

CEO

CHO Pharma has no CEO, or we have no data on them.

Board Members

Experienced Board: 6586's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/15 00:00
End of Day Share Price	2022/05/13 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31